{
  "id": 728410,
  "title": "NeuroScientific locks in key US FDA meeting",
  "url": "https://urgent.news/2026/08/13/neuroscientific-locks-in-key-us-fda-meeting",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-13T03:12:44.000Z",
  "source": {
    "name": "The Sydney Morning Herald",
    "slug": "the-sydney-morning-herald",
    "url": "https://www.smh.com.au/business/companies/neuroscientific-locks-in-key-us-fda-meeting-20260813-p60o2o.html?ref=rss"
  },
  "original_language": "en",
  "account": null,
  "summary": "NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Age",
        "title": "NeuroScientific locks in key US FDA meeting",
        "url": "https://urgent.news/2026/08/13/neuroscientific-locks-in-key-us-fda-meeting-728440",
        "published": "2026-08-13T03:12:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}